Sintilimab-induced autoimmune diabetes: A case report and review of the literature

doi:10.12998/wjcc.v10.i4.1263

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 4

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4445)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

232

WORD

HTML

2226

Figures (1-3)

316

Tables (1-4)

334

Sum=3201

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

321

Download

923

Sum=1244

Feb 6, 2022 (publication date) through Jan 31, 2025

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Feb 6, 2022; 10(4): 1263-1277
Published online Feb 6, 2022. doi: 10.12998/wjcc.v10.i4.1263

Full Size Figure Download Figure

Figure 1 Mechanism of action of PD-1/PD-L1 immune checkpoint inhibitors. PD-1: Programmed death-1; PD-L1: Programmed death-ligand 1.

Citation: Yang J, Wang Y, Tong XM. Sintilimab-induced autoimmune diabetes: A case report and review of the literature. World J Clin Cases 2022; 10(4): 1263-1277
URL: https://www.wjgnet.com/2307-8960/full/v10/i4/1263.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i4.1263